Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from SABS

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside higher research and development spending. Chief Executive Officer Sa

MarketBeat

"Ozzy stood up, produced a Zippo lighter from his back pocket, and set Bill Ward's beard on fire": A personal insight into the chaotic, beautiful mind of Ozzy Osbourne

20 years of audiences with his royal highness, the Prince of Darkness

Metal Hammer

From Black Sabbath to Napalm Death: these are the 10 greatest metal bands from Birmingham

10 brilliant metal bands that show Birmingham really is the home of metal

Metal Hammer

From analysis to the latest developments in health,
read the most diverse news in one place.

"Nobody has ever sung a heavy metal song better than Ronnie did": A tribute to Ronnie James Dio

Ronnie James Dio: July 10, 1942 – May 16, 2010

Metal Hammer

"Ozzy jumped from one subject to another with astonishing rapidity, like some frantic pigeon": A mind-mincing encounter with Black Sabbath on the Sabotage tour

By 1976, Black Sabbath already had a huge heritage to live up to. We joined them on the road in Portsmouth

Metal Hammer

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185

SAB Biotherapeutics Inc (NASDAQ:SABS) said that due to low hospitalization and death rates in the trial, the National Institutes of Health's (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19 trial. SAB-185 was being assessed as part of Phase 3 ACTIV-2 master protocol evaluating treatments for COVID-19 in patients with…

Benzinga

On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Trial

SAB Biotherapeutics Inc (NASDAQ: SABS) has

Benzinga

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

National Institutes of Health

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.